Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)
Status:
Completed
Trial end date:
2021-03-10
Target enrollment:
Participant gender:
Summary
The AELIX-002 study aims to evaluate the safety and the immunogenicity of an heterologous
prime-boost regimen with DNA.HTI, MVA.HTI and ChAdOx1.HTI in early diagnosed and treated
HIV-1 positive individuals, males and females,18-60 years of age.